Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

Table 1 Demographic and baseline characteristics (all treatment groups combined)

Characteristic	LEI > 0 (N = 403)	LDI-B > 0 (N = 155)	Integrated analysis set (N = 679)
Age, mean years (SD)^a	51.2 (11.8)	47.8 (12.1)	51.0 (11.9)
Gender, n (%)
Male	166 (41.2)	70 (45.2)	310 (45.7)
Race, n (%)^a
White	379 (94.0)	142 (91.6)	629 (92.8)
Black or African American	1 (0.2)	0 (0.0)	3 (0.4)
Asian	16 (4.0)	12 (7.7)	33 (4.9)
Other/multiple	7 (1.7)	1 (0.6)	13 (1.9)
BMI, kg/m², mean (SD)^a	31.2 (7.8)	29.9 (7.3)	30.2 (7.3)
cDMARD experience, n (%)	231 (57.3)	96 (61.9)	385 (56.7)
MTX at baseline, n (%)	192 (47.6)	81 (52.3)	318 (46.8)
Time since PsA onset, mean years (SD)	11.0 (8.8)	9.7 (8.0)	11.0 (9.3)
Active PSO with BSA ≥ 3%, n (%)^a	241 (65.7)	105 (74.5)	402 (65.4)
Tender joint count (68 joints), mean (SD)^a	25.2 (15.5)	22.2 (13.5)	22.0 (14.9)
Swollen joint count (66 joints), mean (SD)^a	12.5 (9.1)	15.2 (11.3)	11.9 (9.1)
Current enthesitis, n (%)^a	403 (100.0)	108 (69.7)	403 (59.7)
Current dactylitis, n (%)^a	108 (26.8)	155 (100.0)	155 (22.9)
Leeds Enthesitis Index, mean (SD)^a,b	2.9 (1.6)	3.1 (1.6)	2.9 (1.6)
Leeds Dactylitis Index-Basic, mean (SD)^a,c	58.2 (72.0)	56.4 (68.3)	56.4 (68.3)

Abbreviations: BSA body surface area, BMI body mass index, cDMARD conventional disease-modifying antirheumatic drugs, LDI-B Leeds Dactylitis Index-Basic, LEI Leeds Enthesitis Index, MTX methotrexate, N population size, n number in group, PsA psoriatic arthritis, PSO psoriasis, SD standard deviation
^aThere are patients with missing baseline information in some groups; the denominator of a particular baseline measure is the number of patients with non-missing baseline measures
^bSummarized by patients with baseline enthesitis, defined as LEI score > 0
^cSummarized by patients with baseline dactylitis, defined as LDI-B score > 0

ISSN: 1478-6362